BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15184995)

  • 1. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
    Morgan RJ; Synold TW; Gandara D; Muggia F; Scudder S; Reed E; Margolin K; Raschko J; Leong L; Shibata S; Tetef M; Vasilev S; McGonigle K; Longmate J; Yen Y; Chow W; Somlo G; Carroll M; Doroshow JH
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):283-9. PubMed ID: 15184995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.
    Morgan RJ; Synold TW; Gandara D; Muggia F; Scudder S; Reed E; Margolin K; Raschko J; Leong L; Shibata S; Tetef M; Vasilev S; McGonigle K; Longmate J; Yen Y; Chow W; Somlo G; Carroll M; Doroshow JH
    Int J Gynecol Cancer; 2007; 17(2):373-8. PubMed ID: 17362315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
    Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
    Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
    Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
    Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy.
    Morgan RJ; Margolin K; Raschko J; Akman S; Leong L; Somlo G; Scanlon K; Ahn C; Carroll M; Doroshow JH
    J Clin Oncol; 1995 Sep; 13(9):2238-46. PubMed ID: 7666081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
    Raschko JW; Synold TW; Chow W; Coluzzi P; Hamasaki V; Leong LA; Margolin KA; Morgan RJ; Shibata SI; Somlo G; Tetef ML; Yen Y; ter Veer A; Doroshow JH
    Cancer Chemother Pharmacol; 2000; 46(5):403-10. PubMed ID: 11127945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.
    Stiff PJ; Bayer R; Tan S; Camarda M; Sosman J; Peace D; Kinch L; Rad N; Loutfi S
    Clin Cancer Res; 1995 Dec; 1(12):1495-502. PubMed ID: 9815949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
    Forster M; Kaye S; Oza A; Sklenar I; Johri A; Cheung W; Zaknoen S; Gore M
    Clin Cancer Res; 2007 Jul; 13(14):4178-84. PubMed ID: 17634546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
    Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined chemotherapy with weekly paclitaxel and carboplatin for recurrent and refractory epithelial ovarian cancer--phase I study].
    Misawa A; Yasuda M
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1445-52. PubMed ID: 17033235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
    Koensgen D; Stengel D; Belau A; Klare P; Oskay-Oezcelik G; Steck T; Camara O; Mustea A; Sommer H; Coumbos A; Bogenrieder T; Lichtenegger W; Sehouli J;
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):393-400. PubMed ID: 17922272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
    Kimball KJ; Numnum TM; Kirby TO; Zamboni WC; Estes JM; Barnes MN; Matei DE; Koch KM; Alvarez RD
    Gynecol Oncol; 2008 Oct; 111(1):95-101. PubMed ID: 18692224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
    Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
    Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.
    Aghajanian C; Dizon DS; Sabbatini P; Raizer JJ; Dupont J; Spriggs DR
    J Clin Oncol; 2005 Sep; 23(25):5943-9. PubMed ID: 16135465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
    Curt GA; Grygiel JJ; Corden BJ; Ozols RF; Weiss RB; Tell DT; Myers CE; Collins JM
    Cancer Res; 1983 Sep; 43(9):4470-3. PubMed ID: 6347373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBCDA for advanced ovarian cancer patients].
    Fujiwara K; Yamauchi H; Sawada S; Koike H; Mohri H; Ohishi Y; Kohno I
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2373-9. PubMed ID: 1463344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
    Rose PG; Smrekar M; Haba P; Visser C; Beeler JF
    Gynecol Oncol; 2005 Dec; 99(3):714-9. PubMed ID: 16112177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.